目的：系统评价影响HER-2阳性乳腺癌预后的因素。方法：检索国内公开发表的关于HER-2阳性乳腺癌预后相关的文献，依据纳入标准和排除标准，纳入符合要求的文献，并提取相应观测指标的5年生存率，利用Revman 5.3软件行Meta分析。结果：纳入4篇文献。558例患者纳入研究。各指标5年生存率的Meta结果显示，年龄≥35岁患者优于年龄<35岁患者（OR=0.01，95% CI=0.01~0.02，P<0.00001）、无家族史的优于有家族史的患者（OR=0.00，95% CI=0.00~0.00，P<0.00001）、肿瘤<5 cm的患者优于肿瘤≥5 cm的患者（OR=14.83，95% CI=1.03~212.53，P=0.05）、无淋巴结转移的患者优于有淋巴结转移的患者（OR=0.47，95% CI=0.27~0.82，P=0.007）、组织学分级为I、II级的患者优于分级为III级的患者（OR=2.84，95% CI=1.63~4.97，P=0.0002）、病理分型为其他癌的患者优于病理分型为浸润性导管癌的患者（OR=35.5，95% CI=21.71~58.03，P<0.00001）；绝经状态对患者预后无明显影响（OR=0.64，95% CI= 0.26~1.59，P=0.34）。结论：年龄、家族史、肿瘤大小、淋巴结转移、组织学分级、病理分型与HER-2阳性乳腺癌预后有关。绝经状态对预后的影响有待进一步证明。
Prognostic factors for HER-2-positive breast cancer in China: a Meta-analysis
Objective: To systematically assess the factors that influence the prognosis of HER-2-positive breast cancer. Methods: Publicly published domestic studies regarding the prognosis of HER-2-positive breast cancer were searched, and the eligible studies were selected based on the inclusion and exclusion criteria, and then the 5-year survival rates for different observational factors were extracted and Meta-analysis was performed by RevMan 5.3 software. Results: A total of 4 studies with 558 patients were included. Results of Meta-analysis for different observational factors showed that the 5-year survival rate in patients ≥35 years of age was better than that in those <35 years of age (OR=0.01, 95% CI=0.01–0.02, P<0.00001), in patients without family history was better than those with a family history (OR=0.00, 95% CI=0.00–0.00, P<0.00001), in patients with tumor size < 5 cm was better that those with tumor size ≥5 cm (OR=14.83, 95% CI=1.03–212.53, P=0.05), in patients without lymph node metastasis was better than in those with lymph node metastasis (OR=0.47, 95% CI=0.27–0.82, P=0.007), in patients with histological grade I or II was better than in those with histological grade III (OR=2.84, 95% CI=1.63–4.97, P=0.0002), and in patients with other pathological types was better than in those with invasive ductal carcinoma (OR=35.5, 95% CI=21.71–58.03, P<0.00001); the menopausal status had no significant influence on prognosis of the patients (OR=0.64, 95% CI=0.26–1.59, P=0.34). Conclusion: Age, family history, tumor size, lymph node metastasis, histological grade and pathological type are associated with the prognosis of HER-2-positive breast cancer, but the influence of menopausal status on prognosis remains to be identified.